Literature DB >> 2490828

Antihypertensive drug treatment. Potential, expected, and observed effects on stroke and on coronary heart disease.

S MacMahon1, J A Cutler, J Stamler.   

Abstract

The effects of prolonged differences in diastolic blood pressure (DBP) on the risks of stroke and of coronary heart disease (CHD) were estimated from nine major prospective observational studies involving about 420,000 men and women who were followed up for intervals of 6-25 years. The results indicate that a prolonged difference of about 6 mm Hg in DBP was associated with approximately 37% fewer strokes and 23% fewer CHD deaths and nonfatal myocardial infarctions. The effects of equivalent reductions in DBP produced by antihypertensive drug treatment but maintained for only a few years have been estimated in several overviews of randomized trials involving a total of 30,000-40,000 patients. The results of the overviews indicate that treatment reduced the risk of stroke by about 40%, suggesting that most or all the long-term potential benefits for stroke due to lower DBP were achieved within about 3 years of beginning treatment. The risks of nonfatal myocardial infarction and CHD death may have been reduced by about 10% among patients allocated to active treatment; the 95% confidence limits for the difference ranged from about zero to about 20%. Whatever the true effect of treatment on CHD, it would appear somewhat less than the difference in risk estimated from the observational studies for a prolonged difference in DBP of the same size. This apparent shortfall in benefit may reflect a long time-course for changes in DBP to have their full effects on CHD, possible adverse side effects of the principal trial treatments, or both.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2490828     DOI: 10.1161/01.hyp.13.5_suppl.i45

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Clinical trials and clinical practice in the elderly. A focus on hypertension.

Authors:  M E Kitler
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 2.  Effects of antihypertensive therapy on hypertensive vascular disease.

Authors:  J B Park; E L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 3.  Pharmacoeconomic considerations in the management of hypertension.

Authors:  H Pardell; R Tresserras; P Armario; R Hernández del Rey
Journal:  Drugs       Date:  2000       Impact factor: 9.546

4.  A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year.

Authors:  Robert H Schneider; Charles N Alexander; Frank Staggers; David W Orme-Johnson; Maxwell Rainforth; John W Salerno; William Sheppard; Amparo Castillo-Richmond; Vernon A Barnes; Sanford I Nidich
Journal:  Am J Hypertens       Date:  2005-01       Impact factor: 2.689

Review 5.  Treatment of hypertension based on both systolic and diastolic pressure could influence the cost of therapy.

Authors:  M Safar
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

Review 6.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.